Capricor Therapeutics (CAPR) Operating Leases (2021 - 2026)

Capricor Therapeutics' Operating Leases history runs 6 years deep, the most recent figure standing at $13.9 million for Q1 2026.

• In Q1 2026, Operating Leases rose 3322.65% year-over-year to $13.9 million; the TTM figure through Mar 2026 stood at $13.9 million (up 3322.65% YoY), while the FY2025 annual figure was $14.3 million, up 2223.55% from the prior year.
• Operating Leases for Q1 2026 stood at $13.9 million, down from $14.3 million in the prior quarter.
• The five-year high for Operating Leases was $14.4 million in Q3 2025, with the low at $194603.0 in Q2 2025.
• The 5-year median for Operating Leases is $1.7 million (2023), against an average of $3.6 million.
• The sharpest annual moves came in 2025 and 2026: Operating Leases slumped 81.36% in 2025, then soared 3322.65% in 2026.
• Capricor Therapeutics' Operating Leases stood at $1.9 million in 2022, then declined by 20.83% to $1.5 million in 2023, then plunged by 58.55% to $616315.0 in 2024, then soared by 2223.55% to $14.3 million in 2025, then dropped by 2.63% to $13.9 million in 2026.
• Business Quant data shows CAPR's Operating Leases at $13.9 million in Q1 2026, $14.3 million in Q4 2025, and $14.4 million in Q3 2025.